EnteroBiotix Expands Headcount and Premises to Advance Microbiome Drug Pipeline

Glasgow, Scotland – 27 October 2021 – EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an increased headcount. This expansion follows the company’s successful $21.5M Series A fundraising announced in September.

Read the full release here.